SARC016

Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors

TYPE OF SARCOMA: Refractory Malignant Peripheral Nerve Sheath Tumors
DRUG: Everolimus and Bevacizumab

ACCRUAL STATUS: Completed

OVERALL STUDY PRINCIPAL INVESTIGATOR:
Brigitte C. Widemann, MD
National Cancer Institute (NCI)

CLINICALTRIALS.GOV IDENTIFIER: NCT01661283

FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV

To contact the study research staff: